SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(del Favero J)
 

Sökning: WFRF:(del Favero J) > Prevention of chemo...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005245naa a2200625 4500
001oai:DiVA.org:liu-50326
003SwePub
008091011s2006 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-503262 URI
024a https://doi.org/10.1093/annonc/mdj0782 DOI
040 a (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
100a Roila, F.u Medical Oncology Division, Silvestrini Hospital, 06156S Andrea delle Fratte, Perugia, Italy4 aut
2451 0a Prevention of chemotherapy- and radiotherapy-induced emesis :b Results of the 2004 Perugia International Antiemetic Consensus Conference
264 1b Elsevier BV,c 2006
338 a print2 rdacarrier
520 a Background: In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the available published trials and provided nearly similar recommendations. Nonetheless, small differences in emetic risk categories and treatment recommendations led to confusion in antiemetics selection. With the emergence of new findings and agents since the guidelines were initially published, many of the oncology professional societies have updated the antiemetic guidelines. Materials and methods: A literature review up to March 2004 was carried out using MEDLINE with evaluation of the evidence by an expert panel composed of 23 oncology professionals in clinical medicine, medical oncology, radiation oncology, oncology nursing, statistics, pharmacy, medical policy and decision making, and pharmacology. The experts represented nine oncology professional societies and came from 11 different countries on four continents. Results: Recommendations on antiemetic regimens to prevent emesis induced by high, moderate, low and minimal risk chemotherapy were suggested as well as management of anticipatory emesis. Furthermore, recommendations for refractory emesis, emesis induced by high-dose chemotherapy and radiotherapy and for antiemetics in children receiving chemotherapy were elaborated. Conclusions: Recommendations about antiemetic prophylaxis in patients receiving treatment with chemo- and radiotherapy have been updated by representatives of nine oncological organizations. © 2005 European Society for Medical Oncology.
653 a 5-HT3-receptor antagonists
653 a Acute emesis
653 a Aprepitant
653 a Delayed emesis
653 a Dexamethasone
653 a Metoclopramide
653 a NATURAL SCIENCES
653 a NATURVETENSKAP
700a Aapro, M.u Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland4 aut
700a Ballatori, E.u Statistics Unit, L'Aquila, Italy4 aut
700a Borjeson, S.u Division of Nursing Science, Linkoping University, Linkoping, Sweden4 aut
700a Clark-Snow, R.A.u University of Kansas Cancer Center, Kansas City, KS, United States4 aut
700a Del, Favero A.u Del Favero, A., Department of Internal Medicine and Oncological Sciences, Perugia, Italy4 aut
700a Einhorn, L.H.u Walther Cancer Institute, Indianapolis, IN, United States4 aut
700a Feyer, P.u Viventes Clinics Berlin-Neukölln, Berlin, Germany4 aut
700a Gralla, R.J.u New York Lung Cancer Alliance, New York, NY, United States4 aut
700a Grunberg, S.M.u University of Vermont, Burlington, VT, United States4 aut
700a Herrstedt, J.u Copenhagen University Hospital, Copenhagen, Denmark4 aut
700a Hesketh, P.J.u Caritas St. Elizabeth's Medical Center, Boston, MA, United States4 aut
700a Kaiser, R.u University Clinic, Goettingen, Germany4 aut
700a Koeller, J.u University of Texas Health Science Center, San Antonio, TX, United States4 aut
700a Kris, M.G.u Memorial Sloan-Kettering Cancer Center, New York, NY, United States4 aut
700a Maranzano, E.u Radiation Oncology Center, 'S.S. Maria' Hospital, Terni, Italy4 aut
700a Molassiotis, A.u School of Nursing, University of Manchester, Manchester, United Kingdom4 aut
700a Olver, I.u Royal Adelaide Hospital Cancer Center, Adelaide, SA, Australia4 aut
700a Osoba, D.u QOL Consulting, West Vancouver, BC, Canada4 aut
700a Rapoport, B.L.u The Medical Oncology Centre of Rosebank, Johannesburg, South Africa4 aut
700a Rittenberg, C.u Rittenberg Oncology Consulting, Metaire, LA, United States4 aut
700a Tonato, M.u Perugia Regional Cancer Center, Perugia, Italy4 aut
700a Warr, D.u Princess Margaret Hospital, University of Toronto, Toronto, Ont., Canada4 aut
710a Medical Oncology Division, Silvestrini Hospital, 06156S Andrea delle Fratte, Perugia, Italyb Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland4 org
773t Annals of Oncologyd : Elsevier BVg 17:1, s. 20-28q 17:1<20-28x 0923-7534x 1569-8041
856u https://doi.org/10.1093/annonc/mdj078
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-50326
8564 8u https://doi.org/10.1093/annonc/mdj078

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy